Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제 71 기) 2026년 01월 01일–2026년 03월 31일” and contains comprehensive company overviews, business descriptions, detailed financial statements, notes, and management discussion for the first quarter of fiscal year 2026. This matches the definition of an Interim/Quarterly Report, not merely an announcement or summary. Therefore, it is classified as IR (Interim/Quarterly Report). Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 82% confidence The document is a provisional (잠정) quarterly operating performance announcement for Q1 2026, providing key financial highlights (sales, operating profit, net income) without full financial statements. This matches an initial earnings release rather than a full interim report or other filing. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-05-12 Korean
매매거래정지및정지해제(중요내용공시)
Delisting Announcement Classification · 95% confidence The document is a notice about the suspension and resumption of trading for JW중외제약 shares due to an important disclosure related to business suspension. It includes specific dates and times for the trading halt and resumption, references regulatory rules, and explicitly states the trading halt and its lifting. This matches the definition of a Delisting Announcement or Trading Suspension Notice. Since the document is about trading suspension and resumption, it fits best under the Delisting Announcement (DLST) category, which covers official notices about stock removal or trading halts. The document is short and focused on this announcement, not a full report or financial data.
2026-04-30 Korean
주요사항보고서(영업정지)
Regulatory Filings Classification · 95% confidence The document is a '주요사항보고서(영업정지)' which translates to a 'Material Event Report (Business Suspension)'. It is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing. The content details an administrative business suspension of certain pharmaceutical products for 3 months due to violations of pharmaceutical laws, including specifics on sales impact and compliance measures. The document is short (1538 characters) and serves as a notification of a significant event affecting the company rather than a full financial report or detailed analysis. It does not contain financial statements or detailed management discussion but is a regulatory announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-30 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 80% confidence The document is a regulatory announcement regarding a major licensing agreement (investment decision) by JW중외제약 with Gan & Lee Pharmaceuticals for a drug candidate. It describes contract details, amounts, milestones, and dates. It is not an annual or interim report, not a dividend or share transaction, not an earnings release or investor presentation, nor a merger or share issue. It is a general corporate disclosure that does not fit more specific categories, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-08 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 85% confidence The document is a voluntary self-disclosure (“자율공시”) of JW중외제약’s corporate value enhancement plan covering targets (CAGR, ROE, dividend increases, share buybacks) and execution status. It is not an earnings release, dividend notice, proxy or voting result, nor is it a formal annual/interim report or investor presentation. It does not announce a financing event, M&A, or share issuance, nor is it a transcript or audit report. As it does not fit any specific category, it falls under the fallback “Regulatory Filings” category (RNS).
2026-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.